Search Results - "Glassman, Fiona"

Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model by Glassman, Fiona Y., Balu-Iyer, Sathy V.

“…[Display omitted] A major complication with enzyme replacement therapy of Factor VIII (FVIII) in Hemophilia A (HA) is the development of anti-drug antibodies…”
Get full text

Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study by Fukuda, Tomoo, Yamagami, Keiko, Kawahata, Kimito, Suzuki, Yuzo, Sasaki, Yoshihiro, Miyagi, Takashi, Jacobs, Iris, Lawo, John-Philip, Glassman, Fiona, Akama, Hideto, Hide, Michihiro, Ohsawa, Isao

“…Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder characterized by recurrent attacks of angioedema. HAE types I and II…”
Get full text

Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins by Nguyen, Nhan H., Glassman, Fiona Y., Dingman, Robert K., Shenoy, Gautam N., Wohlfert, Elizabeth A., Kay, Jason G., Bankert, Richard B., Balu-Iyer, Sathy V.

“…The safety and efficacy of several life-saving therapeutic proteins are compromised due to their immunogenicity. Once a sustained immune response against a…”
Get full text

Biological Function and Immunotherapy Utilizing Phosphatidylserine-based Nanoparticles by Glassman, Fiona Y., Dingman, Robert, Yau, Helena C., Balu-Iyer, Sathy V.

“…Phosphatidylserine (PS) is a naturally occurring anionic phospholipid that is primarily located in the inner leaflet of eukaryotic cell membranes. The role of…”
Get full text

Phosphatidylserine Is Not Just a Cleanup Crew but Also a Well-Meaning Teacher by Glassman, Fiona Y, Schneider, Jennifer L, Ramakrishnan, Radha, Dingman, Robert K, Ramanathan, Murali, Bankert, Richard B, Balu-Iyer, Sathy V

“…Phosphatidylserine (PS) exposure during apoptosis leads to silent clearance of cells without adverse immune reactions to self-proteins. Given the biological…”
Get more information

Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312) by Pawaskar, Dipti, Chen, Xi, Glassman, Fiona, May, Frauke, Roberts, Anthony, Biondo, Mark, McKenzie, Andrew, Nolte, Marc W., Jusko, William J., Tortorici, Michael

“…Factor XII (FXII) is a serine protease involved in multiple cascades, including the kallikrein–kinin system. It may play a role in diseases in which the…”
Get full text

Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Garadacimab (CSL312) in Healthy Japanese and Caucasian Adults by Glassman, Fiona, Goodson, Summer, Bica, Alex, Roberts, Anthony, Akama, Hideto, Asami, Yumiko, Jain, Meena, Acharya, Milin

Get full text

Population Pharmacokinetic/Pharmacodynamic Analysis Of Garadacimab, In Patients With Hereditary Angioedema by Glassman, Fiona, Sharma, Ankur, Cheng, Shen, Johnston, Curtis, De Miguel Lillo, Bernardo, Lawo, John-Philip, Jacobs, Iris, Polhamus, Daniel, Nandy, Partha

Get full text

A Phase 1, Randomized, Open-label, Parallel-group Study Comparing Pharmacokinetic Properties Of Garadacimab Administered By Subcutaneous Pre-filled Syringe Assembled To Autoinjector/Pre-filled Pen Versus Pre-filled Syringe Assembled To Needle Safety Device In Healthy Adults by Glassman, Fiona, Lawo, John-Philip, Bica, Alex, Roberts, Anthony, Kormann, David, Miethke, Soeren, Dziadowiec, Iwona, Caltabiano, Stephen, Jacobs, Iris, Puchalski, Thomas

Get full text

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous and Intravenous Garadacimab Following Single‐Dose Administration in Healthy Japanese and White Adults by Glassman, Fiona, Lawo, John‐Philip, Bica, Mihai Alexandru, Roberts, Anthony, Pawaskar, Dipti, Akama, Hideto, Jain, Meena, Goodson, Summer

“…Garadacimab, an activated factor XII (FXIIa) inhibitor monoclonal antibody, is being evaluated for the long‐term prophylaxis of hereditary angioedema. Here, we…”
Get full text

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial by Craig, Timothy J, Reshef, Avner, Li, H Henry, Jacobs, Joshua S, Bernstein, Jonathan A, Farkas, Henriette, Yang, William H, Stroes, Erik S G, Ohsawa, Isao, Tachdjian, Raffi, Manning, Michael E, Lumry, William R, Saguer, Inmaculada Martinez, Aygören-Pürsün, Emel, Ritchie, Bruce, Sussman, Gordon L, Anderson, John, Kawahata, Kimito, Suzuki, Yusuke, Staubach, Petra, Treudler, Regina, Feuersenger, Henrike, Glassman, Fiona, Jacobs, Iris, Magerl, Markus

“…Hereditary angioedema is a rare and potentially life-threatening genetic disease that is associated with kallikrein–kinin system dysregulation. Garadacimab…”
Get full text

Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pump by Wasserman, Richard L, Cunningham-Rundles, Charlotte, Anderson, John, Lugar, Patricia, Palumbo, Michael, Patel, Niraj C, Hofmann, Jutta, Glassman, Fiona, Rogers, Eileen, Praus, Michaela, Rojavin, Mikhail A

“…A novel, Investigational Wearable Infusor (IWI) was evaluated in a randomized, controlled, crossover, open-label study to determine if its delivery of…”
Get full text

Phosphatidylserine-based Nanoparticles for Tolerance Induction Towards Therapeutic Proteins by Glassman, Fiona Yau

“…Phosphatidylserine (PS) is the most abundant negatively charged phospholipid in the cell membrane. Despite comprising 12% of total phospholipid and being…”
Get full text